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Summary
Emigration of leukocytes from the blood into the tissues is critical in controlling lymphocyte
patrolling in different lymphatic organs and in leukocyte accumulation at sites ofinflammation.
During the first stage of the extravasation process, leukocytes bind to the endothelial lining of
vessels. At the molecular level, several adhesion molecules on leukocytes and endothelial cells
function as receptor-ligand pairsin mediating this dynamic interaction. Recently, we have identified
a novel human endothelial cell molecule, vascular adhesion protein i (VAP-1), that mediates
lymphocyte binding (Salmi, M., and S. Jalkanen. 1992. Science [Wash. DC] 257:1407). VAP-1
was initially characterized by mAb 1132 which inhibits lymphocyte adhesion to high endothelial
venules (HEV) and to purified VAP-1 protein. Here we report the location and function ofVAP-1
in normal and inflamed tissues in humans. VAP-1 is abundant in HEV of lymphatic organs belonging
to the peripheral lymph node system, but considerably less is expressed in vessels of mucosa-
associated lymphatic tissues. A subset of venules in most normal nonlymphatic tissues like skin,
brain, kidney, liver, and heart is also VAP-1 positive. In addition to vessels, VAP-1 is distributed
on a few other cell types, most notably in dendritic-like cells of germinal centers. At sites of
inflammation, such as in inflammatory bowel diseases and chronic dermatoses, expression ofVAP-1
is clearly increased. The induced VAP-1 is functional, since mAb 1132 inhibits lymphocyte binding
to inflamed lamina propria venules by -60%. Thus VAP-1 is an endothelial adhesion molecule
that undernormal conditions is expressed mainly in HEV oflymphatic tissues. However, expression
of functional VAP-1 in vivo is upregulated during an inflammatory reaction at other sites as
well. Inducibility ofVAP-1 suggests that it may play a significant role, not only in recirculation
of lymphocytes, but also in controlling entry of leukocytes into sites of inflammation.
T
he efficiency ofimmune defense is largely dependent on
the ability ofleukocytes to continuously survey different
anatomical locations in the body and to rapidly accumulate
at sites of antigenic insult. To perform this function, leuko-
cytes must first bind to vascular endothelium and then trans-
migrate between the endothelial cells into the underlying
tissue. Leukocyte-endothelial cell interactions are mediated
by regulated function of several adhesion molecules on both
cell types (for reviews see references 1-8). Engagement ofcer-
tain endothelial cell adhesion receptors by theirleukocyte coun-
terparts results in a complex series of events where initial weak
and transient adherence is followed by stable binding and ex-
travasation of leukocytes (6-8). On human endothelium, at
leastE-selectin (9), P-selectin (10, 11), intercellular adhesion
molecule 1 (ICAM-1) (12), ICAM-2 (13), vascular cell adhe-
sion molecule 1 VCAM-1 (14), and peripheral lymph node
addressin (PNAd)/glycosylation-dependent cell adhesion mol-
ecule 1 (G1yCAM-1) (15, 16) have a well-established role in
supporting_leukocyte binding during different steps of the
migration cascade.
We have recently characterized a novel endothelial cell adhe-
sion antigen called vascular adhesion protein 1 (VAP-1) that
mediates lymphocyte binding to high endothelial venules
(HEV) in peripherallymph nodes, tonsils, and inflamed synovia
in humans (17). In contrast, VAP-1 plays only a marginal
role in adherence oflymphocytes to normal mucosa-associated
lymphatic tissues and in the binding of neutrophils to ton-
sillar HEV VAP-1 is distinct from all the other currently
known endothelial cell ligands involved in leukocyte binding
when judged by several criteria like tissue and cell distribu-
tion, molecular weight, function, and NH2-terminal amino
acid sequence (17). In the present study we have examined
the distribution of VAP-1 in several normal and inflamed
organs and tissues in humans and its function in inflammation.
Materials and Methods
Antibodies.
￿
1B2 is an inhibitory mAb (mouse IgGI) against
VAP-1 (17). Polyclonal rabbit Ab against Factor VIII (Dako, Glos-
trup,Denmark) and mAb against CD31(Becton Dickinson & Co.,
Mountain View, CA) were used to assist the identification of en-
dothelial cells. mAb 3G6 (mouse IgGl) against chicken T cells was
used as a negative control. Peroxidase-conjugated rabbit anti-mouse
2255
￿
J. Exp. Med. © The Rockefeller University Press " 0022-1007/93/12/2255/06 $2.00
Volume 178 December 1993 2255-2260Ig and swine anti-rabbit Ig were from Dako, andFITC-conjugated
sheep anti-mouse Ig from Sigma Chemical Co. (St. Louis, MO).
Tissue Specimens. Normal tissue samples from peripheral lymph
node (from two patients), large and small intestine (noninvolved
bowelsegments from nine patients with carcinomas ofgut), kidney
(from three patients), and heart (from five patients) were freshly
obtained from surgical operations or from organ donors. Tonsils
were from 20 tonsilectomies, and othertissues (liver, brain, spinal
cord, peripheral nerve, aorta, vena cava inferior, thyroid, andadrenal)
were from autopsies. All these specimens, except tonsils, were
histopathologically determined to be noninflamed.
Skin samplesfrom noninvolved and diseased area were obtained
from punch biopsies of nine patients suffering from chronic der-
matoses (psoriasis, atopic exzema, andlichen tuber planus). Inflamed
gut specimens were from patients with inflammatory bowel dis-
eases (Crohn's disease and ulcerative colitis) who underwent sur-
gery for therapeutic purposes.
Immunohistochemistry.
￿
Frozen sections were stained by the im-
munoperoxidase method as previously described (17). VAP-1 ex-
pression in bowel andskin samples(normalandinflamed) wasana-
lyzed by two independent readers from coded samples without
knowledge on the diagnosis. Thenumber of VAP-1positive venules
was semiquantitatively scored as follows: (-) no positive vessels
in the sample; (+) occasional positive vessels in the sample-less
than five vessels/x100 field; (+ +) 5-10 positive vessels/x100 field;
(+++)11-19 positive vessels/x100 field; and(++++) 20 or more
positive vessels/x100 field.
For confocal microscopy, frozen sections from tonsil were stained
with 1132 andFITC-conjugated sheep anti-mouse Ig. Sampleswere
mounted in 50% glycerol, 2x PBS, 0.1% sodium azide, and 100
mg/ml DABCO (1,4-diazabicyclo[2.2.2]octane, Sigma Chemical
Co.). Analyses were performed using a beam scanning confocal
fluorescent microscope (EMBLcompactconfocal microscope with
ZeissAxiovert/10 microscope and x100/1.3 oilPlan-Neofluor ob-
jective) with the laser emission at 488 nm.
Endothelial Cell Binding Assays.
￿
Thein vitrofrozen section assay
was done as previously described (18) . In brief, frozen sections from
tonsil andinflamed gutwere treated with mAbs 1112 and3G6 (con-
trol)under constant rotation for30 min at 6°Cbefore adding freshly
isolated PBL (3 x 106/section) onto tissues. After 30 min, nonad-
herent cells were gently tipped off, and adherent cells were fixed
with 2% glutaraldehyde in cold PBS. Sections were then stained
with FITC-conjugatedanti-Factor VIII Ab, and only lymphocytes
adherent to Factor VIII-positive venuleswere countedusingdark-
field microscopy and epi-illumination. At least 150 vessels were
counted per sample.
In Vitro Induction Experiments.
￿
Human hybrid endothelial cell
line (HEC; a gift from H. Holthofer, University ofHelsinki, Hel-
sinki, Finland) wasgrownin RPMI 1640 supplemented with 10%
FCS, 4MM. L-glutamine, 10 mM Hepes, 100 U/ml penicillin, and
100 Ftg/ml streptomycin in tissue culture bottles at 37°C. HEC
were inducedwith 11,10 (10and100U/ml,Genzyme Corp., Cam-
bridge, MA), IL-2 (10 and 100U/ml; gift from P. Karnani, Laake-
Farmos,Turku, Finland), IL4 (10 and 100 U/ml), 11,6 (10and 100
U/ml), TNF-ca (10 and 200 U/ml), IFN-y (10 and 200 U/ml, all
from Genzyme Corp.) and LPS (10 and 100 ng/ml, from Esche-
richia coli serotype 0:55, Difco Laboratories, Detroit, MI) for 4
and 20 h, and with dibuturyl CAMP (0.5 and 5 pg/ml), PMA (1
and 10 ng/ml), thrombin (0.1 and 1 U/ml; from humanplasma),
histamine (1 and 10 P,g/ml, free base, all from Sigma Chemical
Co.), C5a (1:80 and 1:800, gift from K. Hartiala, University of
Turku, Turku, Finland), and FMLP (10-' and 10' M, Sigma
Chemical Co.) for5min and2h. Allcytokineswere humanrecom-
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Tissue Distribution of VAP-1
Organ/tissue
Tonsil, peripheral lymph node"`
HEV
Interfollicular T cells
Interdigitating cells
Germinal center lymphocytes
Follicular dendritic cells
Follicle mantle cells
Crypt epithelia (tonsil)
Appendix, large intestine
HEV (Peyer's patches)
Lamina propria vessels
Enterocytes, Goblet cells
Smooth muscle
Skin
Keratinocytes, melanocytes
Sweat gland cells
Liver
Hepatocytes
Sinus lining endothelium
Bile duct cells
Kidney
Glomerular cells
Bowman's capsule
Tubular cells
Intertubular vessels
Brain, spinal cord, nerves
Neurons
Glial cells
Skeletal muscle
Muscle cells
Large arteries and veins
Endothelial cells of intima
Media
Adventitia
Heart
Endocardium (endothelial cells)
Muscle cells
Epicardium
Thyroid, adrenal
Secretory epithelium
VAP-1 expression
In all organs, few VAP-1 positive vessels were observed.
t Intensity of staining: + + + , strong; + + , moderate; + , weak;
no staining.binant forms. Inductions were terminated by quickly rinsing the
monolayer twice with ice-cold PBS . Cells were detached with 5
mM EDTA, stained for immunofluorescence, and analyzed using
a FACScan® (Becton Dickinson & Co.) .
Results and Discussion
Distribution ofVAP-1 in NormalHuman Tissues.
￿
Localization
of VAP-1 in normal human organs is summarized in Table
1. In tonsil (Fig . 1 A) and peripheral lymph node (Fig. 1
B), VAP-1 was expressed mainly in vessels . The most promi-
nent staining was seen in endothelial cells ofHEV through
which most lymphocyte trafficking in these organs takes place.
In large-sized vessels (e.g., aorta, vena cava), VAP-1 was
confined to smooth muscle cells of the vessel wall rather than
to the endothelial cell layer. VAP-1 was absent from capil-
laries. In germinal centers, VAP-1 was present in follicular
dendritic cells (Fig. 1 C) . In gut, only a few faintly staining
HEV in organized lymphatic tissues (Peyer's patches and ap-
pendix) and flat-walled venules in lamina propria were ob-
served . Leukocytes, fibroblasts, and epithelial cells were all
VAP-1 negative.
In nonlymphoid organs, VAP-1 was detected mainly in
endothelial cells of a few small-sized venules and in the smooth
muscle layer oflarger vessels . In kidney, arterial endothelium
in glomeruli was VAP-1 negative, whereas intertubular vessels
expressed this antigen (Fig. 1 D) . In liver, sinusoidal en-
dothelium was faintly VAP-1 positive, whereas parenchymal
and ductal cells exhibited no staining. Occasional venules ex-
pressed VAP-1 both in the central nervous system (cerebrum,
cerebellum, and spinal cord) and in peripheral nerves (sciatic
nerve), whereas all neuronal and stromal cells at these loca-
tions were negative (Fig. 1 E) . Smooth muscle cells from
several anatomical locations expressed VAP-1 rather promi-
nently in a granular-like pattern, whereas striated muscle cells
(Fig . 1 F) were negative. In heart, VAP-1 was expressed in
the endothelial cells of endocardium, and in some small vessels
within the myocardium, but VAP-1 was absent from the
epicardium . Cardiac muscle cells displayed marginal VAP-1
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Figure 1 .
￿
Expression of VAP-1
in normal human tissues . VAP-1 is
prominently expressed in HEV
(arrows) in tonsil (A) andperipheral
lymph node (B), whereas lympho-
cytes are negative . Dendritic-like
cells in germinal centers are also
VAP-1 positive (C ; two germinal
centers [gc] in tonsil are outlined
[dashed lines] and one HEV in the
interfollicular area is pointed out
[arrow]) . In kidney, glomerular (go
endothelium lacks VAP-1, but in-
tertubular vessels (arrow) display
positive reactivity (D) . VAP-1 is ab-
sent from neurons (E, brain) and
skeletal muscle cells (F), but occa-
sional venules (arrows) at these sites
express VAP-1 . Original magnifi-
cation x250 .
reactivity. All epithelial cell types studied (including both
squamous and glandular epithelium) lacked VAP-1 . Thus,
VAP-1 is mainly expressed on HEV in tissues belonging to
the peripheral lymph node endothelial recognition system .
However, as is the case with all other currently known en-
dothelial adhesion molecules (11-13, 15, 19-20), VAP-1 is
not specific for endothelial cells : it is present in dendritic-like
cells in germinal centers and in smooth muscle cells . Interest-
ingly, a functional role forVCAM-1 in dendritic and muscle
cells has been reported (21-23), emphasizing the diversity
of functions that can be mediated by a single adhesion
molecule .
VAP-1 Is Localized in Cytoplasmic Granules and on the Cell
Surface ofHEV . Using confocal microscopy, it was readily
discernible that VAP-1 was present on the luminal surface
ofHEV as well as in discrete granules within the cytoplasm
(Fig. 2) . Granular staining suggests that VAP-1 may be stored
intracellularly . The identity ofVAP-1 positive vesicles remains
unknown at present, but it will be interesting to determine
Figure 2. Location of VAP-1 in
HEV In tonsil HEV, VAP-1 is present
both (A) on luminal cell surface and
(B) in cytoplasmic granules of en-
dothelial cells (arrows).XYscans from
two differentHEV ofone tonsil were
obtained using confocal microscopy.
In the images cross-sections of the
vessels are shown. (L) Lumen of the
vessel ; (n) endothelial cell nuclei ; (Inn)
basement membrane (dashed line) .
Original magnification x2500 (op-
tical plus electronic).whether they are Weibel-Palade bodies, for example, where
P-selectin is known to reside (10, 11) .
VAP-1 Is Inducible In Viva
￿
Since many of the known en-
dothelial adhesion molecules (ICAM-1, VCAM-1, E- and
P-selectin ; 3, 4, 24, 25) are inducible in inflammation, we
next investigated the possible association between VAP-1 syn-
thesis and inflammatory status oftissues. As described above,
VAP-1 was only expressed at a low level in some venules of
normal, noninflamed gut (Fig . 3 A) . In contrast, gut speci-
mens from patients with inflammatory bowel diseases dis-
played a markedly increased expression ofVAP-1 (Table 2) .
In the inflamed mucosa, VAP-1 was induced both in the flat-
walled venules of the lamina propria (Fig. 3 B) and in the
HEV-tike venules in organized lymphatic follicles (Peyer's
patches, Fig. 3 C) .
In skin, chronic inflammation was also accompanied with
increased synthesis of VAP-1 . In samples from the derma-
tosis lesion and from macroscopically noninvolved skin area
of the same patient that were simultaneously biopsied and
stained, the number of VAP-1 positive venules in the upper
dermis was consistently higher in the inflamed samples than
in the controls. Using the semiquantitative scoring system,
VAP-1 expression increased from + to + + in one, from +
to + + + in two, from + + to + ++ in two, from ++
to + + + + in two, and from + + + to + + + + in two pa-
tients . Moreover, prominent perivascular leukocyte infiltrates
were constantly associated with VAP-1 positive vessels (data
not shown) . The expression ofVAP-1 in normal gut and skin
specimens may be due to the systemic nature of the diseases
from which the tissue donors were suffering.
VAP-1 Mediates Binding to the Inflamed Mucosa .
￿
To study
the function of the in vivo induced VAP-1 in the inflamed
Figure 3 . VAP-1 is upregu-
lated in the inflamed gut. In
normal gut, only a few faintly
positive vessels in the lamina
propria are observed (A ; in this
area, venules are practically nega-
tive for YAP1). In the inflamed
gut (ulcerative colitis), numerous
VAPI positive venules (arrows) are
seen both in (B) lamina propria
and in (C) organized lymphoid
follicles. Endogenous peroxi-
dase-containing cells (mast cells)
show nonspecific reactivity. (e)
Epithelial cells of the gut ; (lp)
lamina propria . Original magni-
fication x250.
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Table 2 .
￿
Induction of VAP-1 in Inflammatory Bowel Diseases
Bowel specimens were from patients operated on for Crohn's disease,
ulcerative colitis, and tumors (uninvolved area oftumor samples represents
normal samples). Number ofVAP-1 positive venules in each sample was
scored (- to + + + +) as described in Materials and Methods .
mucosa, endothelial cell binding assays were performed . mAb
1132 inhibited lymphocyte binding to small Factor VIII-posi-
tive venules in the lamina propria by -60% in two different
gut samples that abundantly expressed VAP-1 (Fig. 4) . Thus,
expression ofVAP-1 is markedly increased in chronic inflam-
mation, and VAP-1, together with other endothelial adhe-
sion molecules, appears to be capable of targeting appropriate
leukocyte influx into sites of immunological challenge at
different anatomical locations.
VAP-1 Expression In Vitro Is Not Induced by Known Inflam-
matoryMediators .
￿
13 inflammatory cytokines, mitogens, and
B
Binding to
￿
mAb
Tonsil HEV 3G6
1B2
Lamina propria
￿
3G6
venules 1132
Figure 4. The inflammation-
inducedVAPl mediates lymphocyte
binding. A frozen section binding
assay was performed, in which
binding ofPBL to Factor VIII posi-
tive venules in inflamed lamina
propriawas analyzed. (A) Specificity
oftheassay. PBL (darkspots) adhere
to venules (broken line), but not to
the leukocyte-rich stroma between
thevessels. The focus ofthemicro-
graph is at the level of lymphocytes,
and therefore the underlying tissue
seems blurred . (Ll~ Lamina propria .
(B) Inhibition assays were done by
preincubating tissue sections with
mAbs 1B2 and 3G6 . Results are
presented as percent control binding
with standard errors (i.e., binding
ofPBL in the presenceofmAb 3G6
defines 100% binding) .
% of maximal binding
Specimen n - + + +
VAP-1
+ + + + +
Normal 9 0 5 3 1 0
Crohn 7 0 0 2 3 2
Ulcerative colitis 7 0 0 0 5 2secretagogues were tested with HEC in an attempt to define
the mediators that areresponsible for theinduction of VAP-1
in vivo. HEC (Factor VIII-positive, P-selectin-positive cells,
on whichICAM-1 is induciblewith TNF-a) seem to resemble
human umbilical vein endothelial cells that are commonly
used as endothelial cell models (data not shown). HECcells
were induced with two differentconcentrations of each medi-
ator for two time periods(see MaterialsandMethods). How-
ever, none ofthe mediators tested, many of which areknown
to be involved in the regulation of expression of other en-
dothelial cell antigens, had any significant effect on VAP-1
expression on the HECsurface(net mean fluorescence inten-
sity [MFI] after induction ranged between -2.3 and +3.0,
mean -0.1; for comparison, ICAM-1 had a net MFI 23.2
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